Gonzalo H Oporto1,2,3,4, Thomas Bornhardt2,5, Verónica Iturriaga2,5, Luis A Salazar6,7. 1. Centro de Biología Molecular & Farmacogenética, Departamento de Ciencias Básicas, Facultad de Medicina, Universidad de La Frontera, Temuco, Chile. 2. Departamento de Odontología Adultos, Facultad de Odontología, Universidad de La Frontera, Temuco, Chile. 3. Núcleo Científico y Tecnológico en Biorecursos (BIOREN), Universidad de La Frontera, Temuco, Chile. 4. Facultad de Odontología, Departamento de Odontología Integral Adultos, Universidad de La Frontera, Avenida Francisco Salazar 01145, edificio L, Oficina 18, Temuco, Región de La Araucanía, Chile. 5. Facultad de Odontología, Departamento de Odontología Integral Adultos, Universidad de La Frontera, Avenida Francisco Salazar 01145, edificio L, Temuco, Región de La Araucanía, Chile. 6. Centro de Biología Molecular & Farmacogenética, Departamento de Ciencias Básicas, Facultad de Medicina, Universidad de La Frontera, Temuco, Chile. luis.salazar@ufrontera.cl. 7. Núcleo Científico y Tecnológico en Biorecursos (BIOREN), Universidad de La Frontera, Temuco, Chile. luis.salazar@ufrontera.cl.
Abstract
OBJECTIVES: This research aimed to evaluate the frequency of single nucleotide polymorphisms (SNPs) in dopaminergic pathway genes (DRD1, DRD2, DRD3, DRD4, DRD5, and MAOB) in patients undergoing bruxism treatment and controls. SUBJECTS AND METHODS: Patients submitted to bruxism treatment were classified in awake bruxism (61 patients), sleep bruxism (26 patients), and awake-sleep bruxism (43 patients). Control group included 59 patients. Association between circadian manifestations of bruxism and SNPs was investigated using Fisher's exact test, chi-squared test, and calculating the odds ratios and their respective 95% confidence intervals. RESULTS: The G allele of DRD2 rs1800497 SNP was associated with a significant risk reduction of awake-sleep bruxism (p = 0.041), while the C allele of DRD3 rs6280 SNP was associated with increased risk of sleep bruxism (p = 0.02), and the C allele of DRD5 rs6283 SNP was associated with decreased risk of awake bruxism (p = 0.01). CONCLUSIONS: To our knowledge, this is the first report exploring the contribution of genetic variants in dopaminergic pathways to bruxism development, considering all circadian manifestations. Our findings indicate a possible genetic influence in the etiology of awake, sleep, and awake-sleep bruxism. Therefore, further research is needed to increase the current understanding of bruxism physiopathology.
OBJECTIVES: This research aimed to evaluate the frequency of single nucleotide polymorphisms (SNPs) in dopaminergic pathway genes (DRD1, DRD2, DRD3, DRD4, DRD5, and MAOB) in patients undergoing bruxism treatment and controls. SUBJECTS AND METHODS: Patients submitted to bruxism treatment were classified in awake bruxism (61 patients), sleep bruxism (26 patients), and awake-sleep bruxism (43 patients). Control group included 59 patients. Association between circadian manifestations of bruxism and SNPs was investigated using Fisher's exact test, chi-squared test, and calculating the odds ratios and their respective 95% confidence intervals. RESULTS: The G allele of DRD2rs1800497 SNP was associated with a significant risk reduction of awake-sleep bruxism (p = 0.041), while the C allele of DRD3rs6280 SNP was associated with increased risk of sleep bruxism (p = 0.02), and the C allele of DRD5rs6283 SNP was associated with decreased risk of awake bruxism (p = 0.01). CONCLUSIONS: To our knowledge, this is the first report exploring the contribution of genetic variants in dopaminergic pathways to bruxism development, considering all circadian manifestations. Our findings indicate a possible genetic influence in the etiology of awake, sleep, and awake-sleep bruxism. Therefore, further research is needed to increase the current understanding of bruxism physiopathology.
Authors: Kenneth Blum; Amanda L C Chen; John Giordano; Joan Borsten; Thomas J H Chen; Mary Hauser; Thomas Simpatico; John Femino; Eric R Braverman; Debmalya Barh Journal: J Psychoactive Drugs Date: 2012 Apr-Jun
Authors: V McGuire; S K Van Den Eeden; C M Tanner; F Kamel; D M Umbach; K Marder; R Mayeux; B Ritz; G W Ross; H Petrovitch; B Topol; R A Popat; S Costello; A D Manthripragada; A Southwick; R M Myers; L M Nelson Journal: J Neurol Sci Date: 2011-06-12 Impact factor: 3.181
Authors: Bernard Lerer; Ronnen H Segman; Heiner Fangerau; Ann K Daly; Vincenzo S Basile; Roberto Cavallaro; Harald N Aschauer; Robin G McCreadie; Stephanie Ohlraun; Nicol Ferrier; Mario Masellis; Massimiliano Verga; Joachim Scharfetter; Marcella Rietschel; Roger Lovlie; Uriel Heresco Levy; Herbert Y Meltzer; James L Kennedy; Vidar M Steen; Fabio Macciardi Journal: Neuropsychopharmacology Date: 2002-07 Impact factor: 7.853
Authors: Kenneth Blum; M C Gondré-Lewis; E J Modestino; L Lott; D Baron; D Siwicki; T McLaughlin; A Howeedy; M H Krengel; M Oscar-Berman; P K Thanos; I Elman; M Hauser; L Fried; A Bowirrat; R D Badgaiyan Journal: Mol Neurobiol Date: 2019-05-23 Impact factor: 5.590
Authors: Zofia Maciejewska-Szaniec; Marta Kaczmarek-Ryś; Szymon Hryhorowicz; Agnieszka Przystańska; Tomasz Gredes; Barbara Maciejewska; Justyna Hoppe-Gołębiewska; Ryszard Słomski; Andrzej Pławski; Agata Czajka-Jakubowska Journal: BMC Oral Health Date: 2021-10-05 Impact factor: 2.757